Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,667 across all filing types
Latest filing 2011-03-13 Capital/Financing Update
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Appendix 3B 8 pages 121.7KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Stock Exchange (ASX) form used for announcing new issues of securities, including allotments of shares upon exercise of options. The text includes detailed information about the allotment of 626 ordinary shares upon exercise of options, the terms of the securities, the purpose of the issue, and the application for quotation of these additional securities on the ASX. It is a regulatory announcement about a capital change event rather than a financial report or management discussion. The document is over 11,000 characters, so it is not a brief announcement of a report publication. The content clearly fits the category of a capital or financing update related to share allotment and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2011-03-13 English
Market Update - Tissue Heart Valve Study 2 pages 923.9KB
Capital/Financing Update Classification · 90% confidence The document is an ASX market update release from bioMD Limited regarding progress in a tissue heart valve study. It describes ongoing research activities, study aims, expected outcomes, and technical details about the ADAPT tissue engineering process. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a company announcement providing an update on a specific project rather than a formal financial report, earnings release, or regulatory filing. It fits best as a Capital/Financing Update (CAP) because it relates to progress in a project that could impact the company's value and commercial prospects, typical of market updates on R&D progress. The document length (6902 characters) and content confirm it is not a brief announcement or a report publication notice, but a substantive update.
2011-03-08 English
Half Year Report / Accounts 20 pages 438.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half Yearly Report (Appendix 4D) for the 6 months ended 31 Dec 2010' and includes detailed financial statements such as the Statement of Comprehensive Income and Statement of Financial Position for the half-year period. It contains a Directors' Report, Audit Report, and financial data for the half-year ended 31 December 2010. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, which is substantial and contains the actual report, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2011
2011-02-28 English
Change in substantial holding 3 pages 648.7KB
Regulatory Filings
2011-02-27 English
Takeover Update and Additional Information 3 pages 164.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 24 February 2011 from bioMD Limited regarding an offer for unlisted Allied Medical Limited. It details the conditions of a proposed off-market takeover offer, including share transactions, option assignments, board appointments, and an indicative timetable for the offer process. The content focuses on corporate actions related to a takeover bid, including share acquisition, option assignments, and board changes post-merger. There are no financial statements, quarterly or annual results, or audit information presented. The document is an announcement of a capital transaction and corporate restructuring rather than a financial report or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6811 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2011-02-23 English
Appendix 3B 8 pages 121.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B - Allotment' and is an official announcement to the Australian Stock Exchange (ASX) regarding the allotment of 3,500,000 ordinary shares upon exercise of options. It includes detailed information about the securities issued, their terms, issue price, purpose, and quotation agreement. The document is a formal notification of a new share issue and application for quotation of additional securities, consistent with the Appendix 3B form used in Australian securities regulation for new issue announcements. It does not contain financial statements, management discussion, or audit information, nor is it a report or presentation. It is clearly an announcement related to share capital changes.
2011-02-16 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.